Chugai Pharmaceutical Japan was founded in 1925. Chugai’s biopharmaceutical and antibody technologies take a leading position in the industry in Japan currently. In 1994 Chugai‘s business began in China with Granocyte® (granulocyte-colony stimulating factor; G-CSF) launch. Aiming to become a top pharmaceutical company, in March 2014 Chugai Pharma China Co., Ltd. was established with the main function of import, manufacturing and sales/marketing. On the 1st of July 2015, Chugai Pharma China Co., Ltd. and Chugai Pharma (Shanghai) Consulting Co., Ltd. integrated into Chugai Pharma China in order to strengthen the pharmaceutical operation for getting further business development in China.
Oncology and bone/joint diseases are positioned as Chugai Pharm China's strategic areas where we accelerate introducing the new products into China market to contribute to the benefit of the medical community and human health in China.
Our vision is to be a top pharmaceutical company in core domain. In our activities we are committed to the highest ethical and moral standards, seek to understand and respect people and cultures, always put patient as the first consideration and care about the global environment. We will continue to meet our goals to fulfill our mission.
We would appreciate your understanding and continuous supports on our efforts and activities.